Trifarotene

Trifarotene, sold under the brand name Aklief, is a medication for the topical treatment of acne vulgaris.^[6][8] It is a retinoid;^[6][9] specifically, a fourth-generation selective retinoic acid receptor (RAR)-γ agonist.^[10]

Trifarotene

Clinical data
Trade names	Aklief, Selgamis
Other names	CD5789
AHFS/Drugs.com	Monograph
MedlinePlus	a620004
License data	US DailyMed: Trifarotene
Pregnancy category	AU: D[1][2] Contraindicated
Routes of administration	Topical
Drug class	Skin and mucous membrane agents
ATC code	D10AD06 (WHO)
Legal status
Legal status	AU: S4 (Prescription only)[1][2] CA: ℞-only[3][4] UK: POM (Prescription only)[5] US: ℞-only[6] Rx-only[7]
Identifiers
IUPAC name 4-[3-(3-tert-Butyl-4-pyrrolidin-1-ylphenyl)-4-(2-hydroxyethoxy)phenyl]benzoic acid
CAS Number	895542-09-3
PubChem CID	11518241
DrugBank	DB12808
ChemSpider	9693029
UNII	0J8RN2W0HK
KEGG	D11225
ChEMBL	ChEMBL3707313
CompTox Dashboard (EPA)	DTXSID30237781
ECHA InfoCard	100.278.901
Chemical and physical data
Formula	C29H33NO4
Molar mass	459.586 g·mol−1
3D model (JSmol)	Interactive image
SMILES CC(C)(C)c1cc(-c2cc(-c3ccc(C(=O)O)cc3)ccc2OCCO)ccc1N1CCCC1
InChI InChI=1S/C29H33NO4/c1-29(2,3)25-19-23(10-12-26(25)30-14-4-5-15-30)24-18-22(11-13-27(24)34-17-16-31)20-6-8-21(9-7-20)28(32)33/h6-13,18-19,31H,4-5,14-17H2,1-3H3,(H,32,33) Key:MFBCDACCJCDGBA-UHFFFAOYSA-N

Trifarotene was granted orphan drug designation for the treatment of congenital ichthyosis by both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).^[11][12] It was approved for medical use in the United States in October 2019.^[8][13][14] In December 2019, its labelling and package leaflet text received a decentralised approval for 16 European countries.^[7]

Medical uses

In the United States, trifarotene is indicated for the topical treatment of acne vulgaris in people nine years of age and older.^[6] In both Canada and Australia, it is indicated for the topical treatment of acne vulgaris of the face and/or the trunk in people twelve years of age and older.^[1][2][3]

Side effects

Most adverse effects of topical trifarotene for the treatment of acne are at the location side and transient, such as application site irritation, allergic dermatitis, skin irritation and sunburn.^[15] Even though systemic absorption is very low,^[16] use of trifarotene is still contraindicated during pregnancy^[17] because of the known risk of teratogenicity of the overall class of drugs trifarotene belongs to, retinoids.

Society and culture

Legal status

Trifarotene was approved for medical use in the United States in October 2019,^[14] in Canada in November 2019,^[3] and in Australia in January 2021.^[1][2]